• Helsinn Group, of Lugano, Switzerland, said it granted Chugai Pharma Marketing Ltd., a wholly owned subsidiary of Chugai Pharmaceutical Co. Ltd., of Tokyo, exclusive commercialization rights to Phase III-stage ghrelin receptor agonist, anamorelin, in Germany, France, Benelux, UK and Ireland.